Oxford Instruments plc has acquired Medical Imaging Resources Inc. (MIR). MIR specializes in the build, lease and service of mobile medical imaging labs.

CVRx Inc. announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the ESC-Heart Failure 2015 Annual Conference in a late-breaking trial session. Results were presented by Prof. Jochen Müller-Ehmsen, M.D., Ph.D., from Asklepios Hospital Altona in Hamburg, Germany.


With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials, it is now possible to create “electronic stents” to monitor a treated lesion site inside a patient’s artery. A Korean-led team recently published their research on the first device of this kind, showing proof of concept in the American Chemical Society journal ACS Nano.[1] 


The U.S. Food and Drug Administration (FDA) has cleared the InvisionECG technology from InvisionHeart. The mobile electrocardiogram (ECG) technology uses a secure cloud-based, healthcare IT platform to capture and manage 12-lead ECGs.


A virtual-heart platform proposed by Stony Brook University researchers and colleagues has received funding from the National Science Foundation (NSF) in the amount of $4.2 million over five years. The platform was designed to improve and accelerate medical-device development and testing.


OrbusNeich has announced that the first U.S. patient has been enrolled in the HARMONEE (Harmonized Assessment by Randomized, Multi-center Study of OrbusNEich's COMBO StEnt) stent study. The study is being conducted under the framework of the joint Japan-U.S. Harmonization-By-Doing (HBD) initiative and will support the company's planned application for Shonin approval in Japan and to meet the feasibility trial requirements in the U.S.

Subscribe Now